Polar Asset Management Partners Inc. Makes New $7.80 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)

Polar Asset Management Partners Inc. bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 22,100 shares of the biotechnology company's stock, valued at approximately $7,798,000.

Other large investors have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $25,000. Dunhill Financial LLC boosted its stake in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 50 shares in the last quarter. Millstone Evans Group LLC bought a new stake in United Therapeutics during the fourth quarter worth about $67,000. MassMutual Private Wealth & Trust FSB boosted its stake in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 58 shares in the last quarter. Finally, Natixis bought a new stake in United Therapeutics during the fourth quarter worth about $85,000. Institutional investors own 94.08% of the company's stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded up $0.18 during mid-day trading on Wednesday, hitting $309.75. 91,287 shares of the company's stock traded hands, compared to its average volume of 442,606. The company's 50-day moving average is $300.00 and its two-hundred day moving average is $339.52. The company has a market capitalization of $13.97 billion, a P/E ratio of 13.60, a PEG ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a 1 year low of $264.33 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business's revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company earned $6.17 EPS. Equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Activity

In related news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $929,678.52. This represents a 79.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,500 shares of company stock worth $17,054,780. 10.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley boosted their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. Wells Fargo & Company reissued an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective for the company in a research report on Monday, April 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $392.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.